Management of painful diabetic neuropathy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 2969-2978

  Tavakoli, Mitra ^a   Malik, Rayaz A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diabetic neuropathy; Pathogenetic treatment; Symptomatic therapy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; EPALRESTAT; GABAPENTIN; IMIPRAMINE; INSULIN; ISOSORBIDE DINITRATE; LAMOTRIGINE; MEXILETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXCARBAZEPINE; OXYCODONE; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; TRANDOLAPRIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANALGESIC ACTIVITY; ANTICHOLINERGIC EFFECT; ANTINOCICEPTION; BRAIN DISEASE; BRAIN EDEMA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIET THERAPY; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FOOT EDEMA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LETHARGY; LOW DRUG DOSE; METABOLIC DISORDER; MUSCLE DENERVATION; NAUSEA; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PANCREAS TRANSPLANTATION; PARESTHESIA; PATIENT EDUCATION; PHYSIOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DIABETIC NEUROPATHIES; HUMANS; PANCREAS TRANSPLANTATION; PHYSICAL THERAPY MODALITIES; THIOCTIC ACID;

EID: 57549107863     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802498149     Document Type: Review

References (93)

1. Mojaddidi M, Quattrini C, Tavakoli M, et al. Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. Curr Diab Rep 2005;5(6):417-22
2. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 2006;22(8):681-5
3. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist 2008;14(1):23-9
4. Tavakoli M, Mojaddidi M, Fadavi H, et al. Pathophysiology of painful diabetic neuropathy and its treatment Curr Pain Headache Rep 2008;12:192-7
5. Corbett CF. Practical management of patients with painful diabetic neuropathy. Diabetes Educ 2005;31(4):523-4
6. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006;29(4):883-7
7. Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005;48(5):805-7
8. Gore M, Dukes E, Rowbotham DJ, et al. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007;11(6):652-64
9. Calcutt NA, Backonja MM. Pathogenesis of pain in peripheral diabetic neuropathy. Curr Diab Rep 2007;7(6):429-34
10. Kelly KG, Cook T, Backonja MM. Pain ratings at the thresholds are necessary for interpretation of quantitative sensory testing. Muscle Nerve 2005;32(2):179-84
11. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48(3):578-85
12. Rogers LC, Bevilacqua NJ, Malik RA, et al. Neuropathy in diabetes: not a knee-jerk diagnosis. J Am Podiatr Med Assoc 2008;98(4):322-32s5
13. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003;20(2):88-98
14. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med 2007;9(2):36
15. Singleton J, Bixby B, Feldman EL, et al. Diet and exercise counselling alone does not prevent long term neuropathy progression in IGT neuropathy. Neurology 2007;68:A410
16. DCCT (Diabetes Control and Complications Trial) Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8
17. UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
18. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-84
19. Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19:870-3
20. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983;46:491-9
21. Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:386-90
22. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2000;57(1):45-51
23. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339(2):69-75
24. Giannarelli R, Coppelli A, Sartini M, et al. Effects of pancreas - kidney transplantation on diabetic retinopathy. Transplant Int 2005;18(5):619-22
25. Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990;322(15):1031-7
26. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997;42(5):727-36
27. Boucek P, Saudek F, Adamec M, et al. Spectral analysis of heart rate variation following simultaneous pancreas and kidney transplantation. Transplant Proc 2003;35(4):1494-8
28. Boucek P, Havrdova T, Voska L, et al. Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas/kidney transplantation. Diabetes Care 2008;31(8):1611-12
29. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007;30(10):2608-12
30. Norden G, Olausson M, Andersen O. A case of painful progressive peripheral neuropathy after successful pancreas transplantation. J Diabetes Complications 1991;5(4):249-2ss51
31. Del Carro U, Fiorina P, Amadio S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007;30(12):3063-9
32. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the Sydney 2 Trial. Diabetes Care 2006;29(11):2365-70
33. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004;21(2):114-21
34. Halat KM, Dennehy CE. Botanicals and dietary supplements in diabetic peripheral neuropathy. J Am Board Family Pract 2003;16(1):47-57
35. Dyck P, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007;30(10):2619-25
36. Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006;29(7):1538-44
37. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24(10):1776-82
38. Fried LF, Forrest KY, Ellis D, et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 200115(3):113-9
39. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352(9145):1978-81
40. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(4):341-50
41. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987;147(8):1442-4
42. Vrethem M, Boivie J, Arnqvist H, et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997;13(4):313-23
43. Sindrup SH, Ejlertsen B, Frøland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:151-3
44. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991;45:3-9
45. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454
46. Sindrup S, Otto M, Finnerup N. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409
47. Dick IE, Brochu RM, Purohit Y, et al. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 2007;8(4):315-24
48. Sindrup SH, Gram LF, Brøsen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;45:135-44
49. Wernicke JF, Gahimer J, Yalcin I, et al. Safety and adverse event profile of duloxetine. Expert Opin Drug Safety 2005;4:987-93
50. Beard SM, Mccrink L, Le TK, et al. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008;242:385-99
51. Guldiken S, Guldiken B, Arikan E, et al. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab 2004;17:247-9
52. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706
53. Wiffen PJ, McQuay HJ, Moore RA. Cochrane Database Syst Rev 2005;(3):CD005451
54. Rull JA, Quibrera R, González-Millán H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5(4):215-18
55. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005;9:543-54
56. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand 2006;113:395-404
57. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177-80
58. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59:S14-7
59. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
60. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother 2006;6:1629-35
61. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31(7):1448-54
62. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 200767(4):569-85
63. Oaklander ALBB. Pregabalin-withdrawal encephalopathy and splenial edema: a link to high-altitude illness? Ann Neurol 2005;58(2):309-12
64. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007;128:169-79
65. Thienel U, Neto W, Schwabe SK, et al. Topiramate Diabetic Neuropathic Pain Study Group: Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004;110(4):221-31
66. Donofrio PD, Raskin P, Rosenthal NR, et al. Capss-141 Study Group: Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther 2005;27(9):1420-31
67. Raskin P, Donofrio PD, Rosenthal NR, et al. Capss-141 Study Group: Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004;63(5):865-73
68. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997;20(10):1594-7
69. Wright JM, Oki JC, Graves L III. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997;31(1):29-34
70. McCartney C, Sinha A, Katz J. A qualitative systematic review of the role of N.-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004;98:1385-1s400
71. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and post herpetic neuralgia. Neurology 1997;48:1212-8
72. Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose - response trials. Anesthesiology 2002;96:1053-61
73. Thisted R, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther 2006;28:1607-18
74. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008;9:660-74
75. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-6
76. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8
77. Eisenberg E, Mcnicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146
78. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994;46(6):517-22
79. Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004;127(Part 7):1606-15
80. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002;25(10):1699-703
81. Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 2003;26:2697-8
82. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19(Suppl 1):S16-21
83. Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004;17(3):163-8
84. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000;23(3):365-70
85. Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005;48(5):817-23
86. Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996;348:1698-701
87. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 2008;31(2):316-21
88. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Alternat Med Rev 2006;11(4):294-329
89. Jiang H, Shi K, Li X, et al. Clinical study on the wrist - ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Trad Chin Med 2006;26(1):8-12
90. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998;39:115-21
91. Valdivia JM, Dellon AL, Weinand ME, Maloney CT Jr. Surgical treatment of peripheral neuropathy: outcomes from 100 consecutive decompressions. J Am Podiatr Med Assoc 2005;95:451-4
92. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Chaudhry V, Stevens JC, et al. Practice advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2006;66:1805-8
93. Backonja MM, Irving G, Argoff C. Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 2006;10:34-8